Joint Formulary & PAD

Carbamazepine - Epilepsy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Modified release tablets
  • Oral suspension
  • Suppositories
  • Tablets
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Carbamazepine
Indication :
Epilepsy
Group Name :
Keywords :
Brand Names Include :
Tegretol
Important Information :
Ensure that the patient is maintained on a specific manufacturer’s product
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Carbamazepine is used to treat.

Committee Recommendations (1)

The PCN supported the principles of switching from brand to generic medications (not recommended in the elderly) as per national guidelines in September 2013 and the proposed place in therapy of the anti-epileptic drugs which is based on NICE guidance was also discussed at that time. Transfer of care documents will be considered at a future PCN.

Please note the MHRA categorisations for each drug in the attached guidance (updated January 2014) and in the link below.